Notice: This company has been marked as potentially delisted and may not be actively trading. Miragen Therapeutics (MGEN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends MGEN vs. PSNL, SERA, BDSX, XGN, BNR, ENZ, OPGN, PMD, BGLC, and ACONShould you be buying Miragen Therapeutics stock or one of its competitors? The main competitors of Miragen Therapeutics include Personalis (PSNL), Sera Prognostics (SERA), Biodesix (BDSX), Exagen (XGN), Burning Rock Biotech (BNR), Enzo Biochem (ENZ), OpGen (OPGN), Psychemedics (PMD), BioNexus Gene Lab (BGLC), and Aclarion (ACON). Miragen Therapeutics vs. Personalis Sera Prognostics Biodesix Exagen Burning Rock Biotech Enzo Biochem OpGen Psychemedics BioNexus Gene Lab Aclarion Personalis (NASDAQ:PSNL) and Miragen Therapeutics (NASDAQ:MGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation. Does the MarketBeat Community favor PSNL or MGEN? Miragen Therapeutics received 152 more outperform votes than Personalis when rated by MarketBeat users. Likewise, 70.45% of users gave Miragen Therapeutics an outperform vote while only 66.47% of users gave Personalis an outperform vote. CompanyUnderperformOutperformPersonalisOutperform Votes11566.47% Underperform Votes5833.53% Miragen TherapeuticsOutperform Votes26770.45% Underperform Votes11229.55% Do analysts rate PSNL or MGEN? Personalis presently has a consensus price target of $6.81, suggesting a potential upside of 101.55%. Given Personalis' stronger consensus rating and higher possible upside, analysts clearly believe Personalis is more favorable than Miragen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Personalis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Miragen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, PSNL or MGEN? Personalis has a beta of 1.94, indicating that its share price is 94% more volatile than the S&P 500. Comparatively, Miragen Therapeutics has a beta of 1.66, indicating that its share price is 66% more volatile than the S&P 500. Do institutionals and insiders believe in PSNL or MGEN? 61.9% of Personalis shares are owned by institutional investors. 4.1% of Personalis shares are owned by insiders. Comparatively, 1.1% of Miragen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is PSNL or MGEN more profitable? Personalis has a net margin of -104.52% compared to Miragen Therapeutics' net margin of -1,393.50%. Personalis' return on equity of -66.07% beat Miragen Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Personalis-104.52% -66.07% -41.34% Miragen Therapeutics -1,393.50%-141.66%-88.74% Which has higher earnings and valuation, PSNL or MGEN? Miragen Therapeutics has lower revenue, but higher earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Miragen Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPersonalis$73.48M3.25-$108.30M-$1.68-2.01Miragen Therapeutics$4.46M17.34-$41.87M-$20.09-0.99 Does the media prefer PSNL or MGEN? In the previous week, Personalis had 6 more articles in the media than Miragen Therapeutics. MarketBeat recorded 6 mentions for Personalis and 0 mentions for Miragen Therapeutics. Personalis' average media sentiment score of 0.07 beat Miragen Therapeutics' score of 0.00 indicating that Personalis is being referred to more favorably in the media. Company Overall Sentiment Personalis Neutral Miragen Therapeutics Neutral SummaryPersonalis beats Miragen Therapeutics on 13 of the 18 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Miragen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGEN vs. The Competition Export to ExcelMetricMiragen TherapeuticsMedical Laboratories IndustryMedical SectorNASDAQ ExchangeMarket Cap$77.34M$3.11B$5.14B$8.84BDividend YieldN/A11.18%5.05%4.07%P/E Ratio-1.8616.41125.0517.04Price / Sales17.34214.171,232.2287.12Price / CashN/A406.7839.9936.27Price / Book2.923.196.956.36Net Income-$41.87M-$32.86M$119.41M$226.00M Miragen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGENMiragen TherapeuticsN/A$19.79-2.2%N/A+25.0%$77.34M$4.46M-1.8645High Trading VolumePSNLPersonalis4.2019 of 5 stars$3.38-2.3%$6.81+101.6%+156.3%$238.80M$73.48M-2.01400SERASera Prognostics0.5095 of 5 stars$6.11+1.3%N/A+235.0%$206.34M$310,000.00-6.17120BDSXBiodesix2.6917 of 5 stars$1.20+0.8%$3.06+155.0%-16.2%$174.56M$49.09M-3.08220Insider TradeNegative NewsGap DownHigh Trading VolumeXGNExagen4.8148 of 5 stars$3.91-6.9%$7.00+78.9%+169.2%$69.03M$52.55M-4.87220Analyst RevisionPositive NewsGap UpHigh Trading VolumeBNRBurning Rock BiotechN/A$5.38+15.9%N/A-48.5%$55.09M$75.70M-1.121,390Gap UpENZEnzo Biochem0.5074 of 5 stars$0.97-1.0%N/A-22.3%$50.85M$31.91M0.00520OPGNOpGenN/A$1.81-9.0%N/A-55.8%$15.13M$3.42M0.00100News CoverageGap DownPMDPsychemedics0.8471 of 5 stars$2.34flatN/A+11.0%$13.78M$22.10M-4.57140BGLCBioNexus Gene LabN/A$0.29-3.3%N/A-22.6%$5.25M$9.77M0.0030ACONAclarion2.9803 of 5 stars$0.18flat$1.50+738.5%-95.9%$1.87M$80,000.000.007News CoveragePositive News Related Companies and Tools Related Companies Personalis Alternatives Sera Prognostics Alternatives Biodesix Alternatives Exagen Alternatives Burning Rock Biotech Alternatives Enzo Biochem Alternatives OpGen Alternatives Psychemedics Alternatives BioNexus Gene Lab Alternatives Aclarion Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MGEN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGEN Stock Alerts